The Longevity Registry

§ — Researched for · Tissue repair & injury recovery

Peptides researched for tissue repair & injury recovery

Several peptides are being researched for tendon, ligament, muscle and gut-lining repair — most prominently BPC-157 and TB-500. As of October 2026, none is approved by the FDA for any use, and the human evidence for injury recovery is limited to small, short studies that FDA reviewers described as underpowered.

A
Approved drug with randomized controlled trials for the approved indication
B
Human clinical data exists, but no approval for the researched use
C
Animal or in-vitro data only, no controlled human trials
D
No published clinical data; use rests on anecdote

Reviewed October 2026 · Sources: FDA, EMA

02 — What is being studied

The research field, in plain terms.

The research field is regenerative signalling: whether short peptide sequences can influence how tendon, ligament, muscle and intestinal lining rebuild after damage. Endpoints under study in animals are collagen organisation at the tendon-to-bone junction, capillary formation in healing tissue, and the integrity of the gut mucosal barrier after chemical or ischaemic injury. Those models are where nearly all of the published data sits.

In humans the picture is much thinner. Trials that exist are small, short and mostly aimed at gastrointestinal indications rather than at sports injury, which is the use that dominates online discussion. Nothing published tracks return-to-sport timelines, re-injury rates or structural healing on imaging against a control group. The distance between the animal literature and any clinical endpoint is the central fact of this field as of October 2026.

03 — The table

Every peptide in this group, with its status.

PeptideResearched forEvidenceRegulatory statusAs of
GHK-CuSkin aging, wound healing, hair growth, gene expression modulation.BNot an approved drug. Topical use is regulated as a cosmetic ingredient. The injectable form was removed from 503A Category 2 on April 15, 2026, and is scheduled for review by the advisory committee at a meeting before the end of February 2027. It is not on the 503A Bulks List.2026-10-22
BPC-157Tendon, ligament and muscle healing; gastrointestinal mucosal protection; ulcerative colitis (the indication FDA reviewed in 2026).CNot FDA-approved for any use. Removed from 503A Category 2 on April 15, 2026, after its nomination was withdrawn — which is not a listing in Category 1. On July 23, 2026, the Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend it for the 503A Bulks List; FDA's own scientists had recommended against. FDA has not decided. It is not on the 503A Bulks List, so it cannot yet be compounded under section 503A.2026-10-22
LL-37Chronic wound infection, biofilm disruption, venous leg ulcers.CNot FDA-approved. Removed from 503A Category 2 on April 15, 2026, and scheduled for review by the advisory committee before the end of February 2027. It is not on the 503A Bulks List.2026-10-22
TB-500Wound healing, cardiac tissue repair after injury, corneal healing.CNot FDA-approved. Removed from 503A Category 2 on April 15, 2026. On July 23, 2026, the advisory committee voted 8–6 (one abstention) to recommend it for the 503A Bulks List, against the advice of FDA's scientists. FDA has not decided; it is not on the list and cannot yet be compounded under section 503A.2026-10-22

04 — Per peptide

Status first, then research.

B

GHK-Cu

Regulatory status · United States · as of October 2026

Not an approved drug. Topical use is regulated as a cosmetic ingredient. The injectable form was removed from 503A Category 2 on April 15, 2026, and is scheduled for review by the advisory committee at a meeting before the end of February 2027. It is not on the 503A Bulks List.

Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026

Researched forSkin aging, wound healing, hair growth, gene expression modulation.

Full profile: GHK-Cu →
C

BPC-157

Regulatory status · United States · as of October 2026

Not FDA-approved for any use. Removed from 503A Category 2 on April 15, 2026, after its nomination was withdrawn — which is not a listing in Category 1. On July 23, 2026, the Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend it for the 503A Bulks List; FDA's own scientists had recommended against. FDA has not decided. It is not on the 503A Bulks List, so it cannot yet be compounded under section 503A.

Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026

Researched forTendon, ligament and muscle healing; gastrointestinal mucosal protection; ulcerative colitis (the indication FDA reviewed in 2026).

Full profile: BPC-157 →
C

LL-37

Regulatory status · United States · as of October 2026

Not FDA-approved. Removed from 503A Category 2 on April 15, 2026, and scheduled for review by the advisory committee before the end of February 2027. It is not on the 503A Bulks List.

Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026

Researched forChronic wound infection, biofilm disruption, venous leg ulcers.

Full profile: LL-37 →
C

TB-500

Regulatory status · United States · as of October 2026

Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. On July 23, 2026, the advisory committee voted 8–6 (one abstention) to recommend it for the 503A Bulks List, against the advice of FDA's scientists. FDA has not decided; it is not on the list and cannot yet be compounded under section 503A.

Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026

Researched forWound healing, cardiac tissue repair after injury, corneal healing.

Full profile: TB-500 →

05 — What the data does not show

The limits of this group.

Faster return to sport, systemic anti-inflammatory benefit and long-term safety have not been demonstrated in humans for any peptide in this group.

06 — Questions for your physician

Six questions worth printing.

  1. 01What is your primary board certification, and in what year did you obtain it?
  2. 02Is this peptide approved for what you are prescribing it for — and if not, what is the legal basis on which you are supplying it?
  3. 03Which human trials support this use, and what were their size and duration?
  4. 04Where does the product come from, and can you show me a certificate of analysis for this batch?
  5. 05What outcome will we measure, when, and what happens if it does not improve?
  6. 06What is the total cost for the first three months, in writing?

Practices near you that offer peptide therapy

Every practice in the registry that lists peptide therapy, sorted by distance and nothing else. You contact the practice directly.

AgeReversalMD

La Jolla, CA

Focus matches this goal: Biological Age & Epigenetics, Cognition & Brain Health, Functional Medicine

No physician listed on the practice website

View profile →Practice website ↗

Ana Casas M.D. Anti-Aging and Regenerative Medicine

Alpharetta, GA

Focus matches this goal: Advanced Blood Biomarkers, Cancer Screening & Early Detection, Cognition & Brain Health

Physician credentials on file

View profile →Practice website ↗

Anazao MD

Steamboat Springs, CO

Focus matches this goal: Cognition & Brain Health, Concierge / Membership Model, DEXA / Body Composition

Physician credentials on file

View profile →Practice website ↗

Angel Longevity Medical Center

Studio City, CA

Focus matches this goal: Biological Age & Epigenetics, Cryotherapy / Sauna / Red Light, Functional Medicine

No physician listed on the practice website

View profile →Practice website ↗

Austin Regenerative Therapy

Austin, TX

Focus matches this goal: Advanced Blood Biomarkers, Cancer Screening & Early Detection, Cognition & Brain Health

Physician credentials on file

View profile →Practice website ↗

BioReset Medical Palm Beach

North Palm Beach, FL

Focus matches this goal: Biological Age & Epigenetics, Cognition & Brain Health, Concierge / Membership Model

No physician listed on the practice website

View profile →Practice website ↗

Listed for transparency, not as an endorsement of any practice, substance or protocol. Most peptides are not FDA-approved for the uses they are offered for.

Reviewed October 2026 · Sources: FDA, EMA

This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.

Most peptides used in longevity practice are not FDA-approved for these uses. Check the status of each substance first.

Practices that offer peptide therapy

All 90 practices nationwide →Las Vegas, NV (3)Naples, FL (3)Newport Beach, CA (4)Orlando, FL (3)St. Petersburg, FL (3)